


DM2 RENALITY

Nuevas dimensiones en enfermedad renal diabética.

ERA-EDTA HIGHLIGHTS

13-16 de junio 2019



Nuevos datos del estudio CREDENCE: Resultados según prevención primaria o secundaria

Dr. José Luis Górriz
Hospital Clínico Universitario de Valencia

Con el patrocinio de:




Iniciativa científica de:




CV Death, MI, or Stroke

Primary Prevention



Secondary Prevention





P interaction = 0.25

CV Death or Hospitalization for Heart Failure

Primary Prevention

Secondary Prevention





P interaction = 0.57

CV Death

Primary Prevention

Secondary Prevention





P interaction = 0.86

Primary Outcome: ESKD, Doubling of Serum Creatinine, or Renal or CV Death

Primary Prevention

Secondary Prevention





P interaction = 0.91

ESKD, Doubling of Serum Creatinine, or Renal Death


Primary Prevention

Secondary Prevention



P interaction = 0.81

Projected Effects on eGFR



ADA Standards of Care Updated With Renal Guidance Based on CREDESCENCE

- *“The CREDESCENCE trial was the first sodium-glucose cotransporter 2 (SGLT2) inhibitor trial to assess renal-specific primary outcomes and ended early due to efficacy. Incorporating these findings into the Standards of Care now gives providers the latest evidence-based recommendations to treat people with type 2 diabetes and diabetes-related chronic kidney disease...”*
 - William T. Cefalu, MD, Chief Scientific, Medical and Mission Officer of the ADA¹
- **Based on the Grade A evidence from the CREDESCENCE trial, the ADA *living guidelines* (updated on June 3, 2019)² propose the following:**
 - “For patients with type 2 diabetes and diabetic kidney disease, consider use of an SGLT2 inhibitor in patients with an eGFR ≥ 30 mL/min/1.73 m² and particularly in those with >300 mg/g albuminuria to reduce risk of CKD progression, cardiovascular events, or both.”

1.American Diabetes Association. <http://www.diabetes.org/newsroom/press-releases/2019/updates-standards-medical-care-diabetes.html>. Accessed June 5, 2019.

2.American Diabetes Association. *Standards of Medical Care in Diabetes—2019*. http://care.diabetesjournals.org/content/42/Supplement_1. Last updated June 3, 2019. Accessed June 5, 2019.